AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02412371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
Study NCT02412371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
Study NCT02412371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsule for oral administration
Study NCT02412371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
Study NCT02412371 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
Study NCT04451967 — intervention group
Intervention type: PROCEDURE
Intervention: thrombolysis
Description: transfer after thrombolysis for STEMI patients within 6h since onset
Study NCT02760498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Study NCT00867204 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP
Description: Patients with clinical indication for ERCP were invited to participate in the Study
Study NCT04133909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
Study NCT04133909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
Study NCT01602029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
Study NCT01602029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
Study NCT01602029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU
Study NCT01602029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Odansetron plus simvastatin
Description: Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
Study NCT02656706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilumumab
Study NCT02656706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02085395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 ® Gel
Study NCT05520372 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous immune enhancement therapy (AIET) for cancer patients
Description: Autologous NK cell and CD8 T cell therapy for cancer patients
Study NCT02437201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liberty Program
Study NCT04206657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg KHK7580
Description: Single oral dose administration of 1mg KHK7580
Study NCT04206657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3mg KHK7580
Description: Single oral dose administration of 3mg KHK7580
Study NCT04206657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6mg KHK7580
Description: Single oral dose administration of 6mg KHK7580
Study NCT04206657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12mg KHK7580
Description: Single oral dose administration of 12mg KHK7580
Study NCT04206657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6mg KHK7580 for 8days
Description: multiple oral dose administration of 6mg KHK7580 for 8days
Study NCT04229264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Oral Apixaban 2.5 mg twice daily for one year
Study NCT04229264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: Acetil Salicilic Acid 100mg once daily for one year
Study NCT04229264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Acetil Salicilic Acid 100mg once daily for one year
Study NCT04229264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75mg once daily for 3 months
Study NCT02296333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: 8 mg intravenous in the skin closure
Study NCT02296333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic
Description: 8 mg intravenous in the skin closure
Study NCT02828787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night.
Study NCT02828787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night.
Study NCT02604875 — intervention group
Intervention type: OTHER
Intervention: observation
Description: blood sampling during 24 hours
Study NCT00466375 — intervention group
Intervention type: GENETIC
Intervention: Cheek cell samples or blood sample (4mL)
Description: DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
Study NCT00466375 — intervention group
Intervention type: GENETIC
Intervention: Cheek cell sample or blood sample (4mL)
Description: DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
Study NCT03465904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Cefaly® Abortive Program device
Description: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.
Study NCT03465904 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cefaly® Abortive Program device
Description: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.
Study NCT00766545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: oral tablet 100 mg, twice daily, over 1 year
Study NCT00766545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of cilostazol
Description: oral tablet, 0 mg twice daily, over 1 year
Study NCT02317432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison of a combined CBT + exercise intervention and enhanced usual care
Study NCT02317432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of a combined CBT + exercise intervention and enhanced usual care
Study NCT06611046 — intervention group
Intervention type: OTHER
Intervention: organ donor
Description: Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group.
Study NCT04064398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration of gastric residuals
Description: Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
Study NCT04657068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
Study NCT04657068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
Study NCT04657068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
Study NCT06729476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uroshield vibrator device
Description: UROSHIELDTM is a small device that generates low-energy surface acoustic waves, which transmit energy to the endotracheal tube through a thin cable attached to the tube. Laboratory studies using catheterized urinary tract models have shown a significant reduction in microbial colonization and reduced development of antimicrobial resistance in UROSHIELDTM device treated individuals.
Study NCT06729476 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Uroshield vibrator device
Description: UROSHIELDTM is a small device that generates low-energy surface acoustic waves, which transmit energy to the endotracheal tube through a thin cable attached to the tube. Laboratory studies using catheterized urinary tract models have shown a significant reduction in microbial colonization and reduced development of antimicrobial resistance in UROSHIELDTM device treated individuals.
Study NCT06729658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar
Description: Experimental group participants will receive Madopar 125mg for 6 days.
Study NCT06729658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group participants will receive placebo for 6 days.
Study NCT03218748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Honest, Open, Proud (HOP)
Description: Three lessons, one for each two-hour session plus one booster session~1. Considering the pros and cons of disclosure:~   Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~2. Different ways to disclose:~   Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~3. Telling one's story:~   Practice how to tell one's story, identifying peers who might be helpful with the coming out process~4. Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience
Study NCT03640572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone marrow analysis to identify disseminated tumour cells
Description: Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
Study NCT03065257 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Resection
Description: Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
Study NCT04852341 — intervention group
Intervention type: DEVICE
Intervention: Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth
Description: observation
Study NCT03874832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study NCT03874832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study NCT00120471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 600-mg tablet taken orally once daily
Study NCT00120471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
Study NCT00120471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Study NCT02459522 — intervention group
Intervention type: OTHER
Intervention: not intervention
Description: This is a cross-sectional study for estimation of diagnostic performance.
Study NCT04091165 — intervention group
Intervention type: OTHER
Intervention: My Plate Calorie Tracker
Description: My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website.
Study NCT00783276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN115
Description: 100 mg single dose
Study NCT02164292 — intervention group
Intervention type: PROCEDURE
Intervention: ALPPS
Description: Associating Liver Partition and Portal vein ligation for Staged hepatectomy
Study NCT02493972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GelPort
Description: Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
Study NCT02493972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: laparotomy will be performed if indication confirmed by manual exploration
Study NCT00463736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Study NCT00463736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Study NCT00315445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
Study NCT00315445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oxycodone/acetaminophen tablets
Description: Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
Study NCT00315445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OXY/APAP
Description: 5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
Study NCT00315445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch (TDS)
Description: Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
Study NCT00465530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intranasal Saline
Study NCT00465530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intranasal Saline
Study NCT00465530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamycin
Description: Intranasal irrigation
Study NCT03717103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
Study NCT04547855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib combined with dose-dense temozolomide
Description: Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
Study NCT03511768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AlF-NOTA-octreotide
Description: One injection of 18F-AlF-NOTA-octreotide
Study NCT03511768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
Study NCT01274533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
Study NCT01651364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
Study NCT01651364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
Study NCT05815134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
Study NCT05815134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
Study NCT00885118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (middle dose)
Description: Placebo tablets once a day
Study NCT00885118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a day
Study NCT00885118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 middle dose tablets once a day
Study NCT00885118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose tablets once a day
Study NCT00885118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (high dose)
Description: Placebo tablets once a day
Study NCT00885118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose tablets once a day
Study NCT00885118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (low dose)
Description: Placebo tablets once a day
Study NCT03225638 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Intramuscular ZENEO® injection of nominal strength
Description: Sodium Chloride (0.9%)
Study NCT03225638 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Intramuscular ZENEO® injection of low strength (upper limit)
Description: Sodium Chloride (0.9%)
Study NCT03225638 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Intramuscular ZENEO® injection of low strength (lower limit)
Description: Sodium Chloride (0.9%)
Study NCT03220308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MYmind mindfulness training
Description: The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.